Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Gain Therapeutics secures $10 million

Natália Pérez-Carmona - Director, Biology at Gain Therapeutics

Lorenzo Leoni email address & phone number

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout

Gain Therapeutics' Small Molecule Approach for CNS Diseases

Home Perspectives from Gain Therapeutics

Gain Therapeutics

What Percentage Of Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Do

Gain Therapeutics Inc Share Price USD0.0001

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data

Home Perspectives from Gain Therapeutics

Gain Therapeutics